AU vs CTVA

The Advanced Deterministic Scorecard shows a Piotroski F-Score of 4/9, indicating stable but not strong financial health, while the absence of an Altman Z-Score prevents a full distress risk assessment. Despite robust profitability metrics—ROE of 38.71%, operating margin of 42.49%, and strong YoY earnings growth of 147.2%—the stock trades at a premium valuation with a P/E of 22.56 and Price/Book of 6.98, above sector averages. Persistent earnings misses over the last four quarters and a weak technical trend score of 10/100 suggest caution, even as analyst consensus remains at 'buy'. The current price of $106.26 sits above the Graham Number of $40.18, reflecting high growth expectations rather than defensive value.

Corteva (CTVA) trades at a premium valuation with mixed profitability trends and strong recent earnings surprises, though near-term earnings growth remains challenged. The stock has underperformed over the past six months (-3.3%) despite solid 1-year and 5-year returns (+16.1%, +85.9%), reflecting macro pressures in agricultural inputs. While revenue growth of 12.6% outpaces the sector average of 6.16%, negative operating margins (-10.31%) and volatile quarterly EPS performance raise concerns about execution and cost structure. Analysts are constructive with a $77.71 target implying 17.7% upside, but recent insider selling adds caution, offsetting an otherwise healthy balance sheet and sustainable dividend policy.